MnTBAP chloride|cas:55266-18-7|西域试剂

MnTBAP chloride,98.0%

产品编号：Bellancom-126397| CAS NO：55266-18-7| 分子式：C₄₈H₂₈ClMnN₄O₈| 分子量：879.15

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-126397		￥1050.00	杭州北京（现货）
Bellancom-126397		￥1700.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MnTBAP chloride

产品介绍

MnTBAP chloride 是一种超氧化物歧化酶 (SOD) 模拟物和过氧亚硝酸盐清除剂。MnTBAP chloride 是一种锰卟啉配合物，具有抗氧化性能。MnTBAP chloride 通过上调 BMPR-II 和抑制 NFκB 信号传导介导抗炎作用。MnTBAP chloride 具有抗氧化性能，具有用于研究慢性肾脏疾病 (CKDs) 纤维化反应的潜力。

生物活性

MnTBAP chloride is a superoxide dismutase (SOD) mimetic and peroxynitrite scavenger. MnTBAP chloride is a manganic porphyrin complex and has anti-oxidative property. MnTBAP chloride mediates anti-inflammatory effects through upregulation of BMPR-II and inhibition of the NFκB signaling. MnTBAP chloride has the potential for the fibrotic response in chronic kidney diseases (CKDs) research.

体外研究

MnTBAP chloride (pretreated 1.14 μM before TGF-β1 of 10 ng/mL) partially but significantly restores E-cadherin reduction and suppresses the induction of α-SMA and vimentin in immortalized mouse proximal tubular cells (mPTCs).
MnTBAP chloride (50 μM; 6 hours) increases BMPR-II mRNA by 1.3-fold at 2 h, but does not affect protein expression of BMPR-II during a time course of 16 h in HUVECs. MnTBAP chloride increases phosphorylation of Smad 1/5, suggesting modulation of the BMP signaling pathway.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

MnTBAP chloride (10 mg/kg; IP; three times per week for twelve weeks) attenuates renal fibrosis in 5/6 Nx mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice with 5/6 nephrectomy (Nx)
Dosage:	10 mg/kg
Administration:	IP; three times per week for twelve weeks
Result:	Attenuated renal fibrosis in 5/6 Nx mice and reduced protein expressions of fibronectin, collagen III in remnant kidneys.

体内研究

MnTBAP chloride (10 mg/kg; IP; three times per week for twelve weeks) attenuates renal fibrosis in 5/6 Nx mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J mice with 5/6 nephrectomy (Nx)
Dosage:	10 mg/kg
Administration:	IP; three times per week for twelve weeks
Result:	Attenuated renal fibrosis in 5/6 Nx mice and reduced protein expressions of fibronectin, collagen III in remnant kidneys.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (113.75 mM; Need ultrasonic)

0.5 M NaOH : 20 mg/mL (22.75 mM; Need ultrasonic)

1M NaOH : 10 mg/mL (11.37 mM; ultrasonic and adjust pH to 8 with NaOH)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.1375 mL	5.6873 mL	11.3746 mL
5 mM	0.2275 mL	1.1375 mL	2.2749 mL
10 mM	0.1137 mL	0.5687 mL	1.1375 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 4.17 mg/mL (4.74 mM); Clear solution

此方案可获得 ≥ 4.17 mg/mL (4.74 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 41.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 4.17 mg/mL (4.74 mM); Clear solution

此方案可获得 ≥ 4.17 mg/mL (4.74 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 41.7 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明